Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry.
Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, Mason M, Guo N, McLean RR, Greenberg JD, Van Voorhees AS. Merola JF, et al. Among authors: bagel j. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2051-2058. doi: 10.1111/jdv.16274. Epub 2020 Jun 9. J Eur Acad Dermatol Venereol. 2020. PMID: 32027420
Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).
Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, Gill A, Pangallo B, Shuler C, Mallbris L, Jackson K. Callis Duffin K, et al. Among authors: bagel j. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107-113. doi: 10.1111/jdv.13768. Epub 2016 Aug 8. J Eur Acad Dermatol Venereol. 2017. PMID: 27500949 Free PMC article. Clinical Trial.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, Chen Z, Eckert L, Chao J, Korotzer A, Rizova E, Rossi AB, Lu Y, Graham NMH, Hultsch T, Pirozzi G, Akinlade B. Silverberg JI, et al. Among authors: bagel j. Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11. Br J Dermatol. 2019. PMID: 30791102 Free PMC article. Clinical Trial.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Among authors: bagel j. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K; IXORA-PEDS study group. Paller AS, et al. Among authors: bagel j. Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15. Br J Dermatol. 2020. PMID: 32316070 Free PMC article. Clinical Trial.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Bagel J, et al. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8. J Eur Acad Dermatol Venereol. 2021. PMID: 32365251 Free PMC article. Clinical Trial.
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.
Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, Wang Y. Van Voorhees AS, et al. Among authors: bagel j. Br J Dermatol. 2021 Oct;185(4):840-842. doi: 10.1111/bjd.20083. Epub 2021 Jul 14. Br J Dermatol. 2021. PMID: 33763874 Free PMC article. Clinical Trial. No abstract available.
133 results